DDInter1627 DDInter1925
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Rufinamide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rufinamide {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rufinamide (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Rufinamide (Compound) binds ALB (Gene) and ALB (Gene) is associated with melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)
Rufinamide (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Rufinamide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Vemurafenib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Rufinamide (Compound) binds ALB (Gene) and ALB (Gene) interacts with ORM1 (Gene) and ORM1 (Gene) is bound by Vemurafenib (Compound)
Rufinamide (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Vemurafenib